Entries by admin

Brolucizumab

1398-05-26 in /by

Brolucizumab (also known as RTH258) is a human­ized single-chain antibody fragment that inhibits all isoforms of VEGF-A with a molecular weight of 26 kDa. “On a molar basis, 6 mg of broluci­zumab equals approximately 12 times the 2.0-mg dose of aflibercept and 22 times the 0.5-mg dose of ranibizumab,” t  “These attributes may confer potential […]

Polypoidal Choroidal Vasculopathy Landmark Studies

1398-05-10 in /by

Medical Treatment of PCV Current treatment plans can be formulated based on three pieces of information: the location of the PCV complex, the baseline vision, and the response to previous therapy. Options available are photodynamic therapy (PDT), anti-VEGF therapy, combination of PDT and anti-VEGF, and laser photocoagulation. PDT The results of the EVEREST clinical trial […]

Protocol V Sheds Light on Managing Mild Diabetic Macular Edema

1398-05-09 in /by

Medscape Ophthalmology Headlines / 2019-07-30 When it comes to the treatment of diabetic macular edema (DME), ophthalmologists have overwhelming evidence to guide their decision-making—but only up to a point. DME consists of three clinical subcategories: center-involved DME (CI-DME) with visual acuity (VA) impairment, CI-DME with good vision, and non–CI-DME.[1] Out of these, the prospective data […]